Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$76.55 USD

76.55
4,300,549

+0.97 (1.28%)

Updated Sep 16, 2025 04:00 PM ET

After-Market: $76.67 +0.12 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DexCom (DXCM) Up 4.6% Since Earnings Report: Can It Continue?

by Zacks Equity Research

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Zacks Equity Research

    DexCom Gains as CMS Announces Criteria for G5 Mobile CGM

    by Zacks Equity Research

    The Centers for Medicare & Medicaid Services published an article clarifying the criteria for coverage of its DexCom (DXCM) G5 Mobile CGM system for patients with diabetes and on intensive insulin therapy.

      Zacks Equity Research

      DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues

      by Zacks Equity Research

      DexCom Inc. (DXCM) reported loss of nine cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 10 cents.

        Zacks Equity Research

        Should You Buy DexCom (DXCM) Ahead of Earnings?

        by Zacks Equity Research

        DexCom (DXCM) looks like an exciting pick for investors as it is poised to beat at earnings season.

          Zacks Equity Research

          DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?

          by Zacks Equity Research

          DexCom, Inc. (DXCM) is set to report fiscal fourth-quarter 2017 results on Feb 28.

            Zacks Equity Research

            DexCom Looking Forward to Strong Revenues in Q4 and 2016

            by Zacks Equity Research

            DexCom, Inc. (DXCM), a renowned medical device company, reported that it expects preliminary, unaudited revenue of approximately $168 million for the fourth quarter ended Dec 31, 2016.

              Zacks Equity Research

              DexCom (DXCM) Gains FDA Approval for G5 Mobile CGM System

              by Zacks Equity Research

              San Diego, CA-based DexCom, Inc. (DXCM), a renowned medical device company, announced the U.S. FDA approval for its G5 Mobile CGM (continuous glucose monitoring) system.

                Zacks Equity Research

                3 Med-Instrument Stocks Poised to Gain this Earnings Season

                by Zacks Equity Research

                2015 is forecasted to be a transition year for the medical instruments sector.